导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.02% | 3175/4773 |
| 近一周 | -1.68% | 2516/5465 |
| 近一月 | -3.20% | 2260/5421 |
| 近一季 | -5.41% | 2061/5231 |
| 近半年 | -0.80% | 1592/4920 |
| 近一年 | -0.30% | 2813/4394 |
| 近两年 | 40.23% | 1891/2954 |
| 近三年 | 27.33% | 1199/2253 |
| 成立以来 | 64.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.54% 3861/4961 |
10.92% 2386/5312 |
- - |
- - |
| 2025 | 18.43% 2317/4813 |
-0.58% 2311/3635 |
2.43% 1567/4076 |
14.82% 2869/4524 |
1.28% 1437/4813 |
| 2024 | 19.56% 518/3463 |
3.99% 490/2808 |
-0.26% 723/3014 |
17.93% 1095/3129 |
-2.25% 2017/3463 |
| 2023 | -11.57% 1414/2656 |
0.49% 1728/2280 |
-3.03% 733/2385 |
-2.38% 671/2515 |
-7.04% 2025/2655 |
| 2022 | -20.57% 981/2207 |
-14.77% 997/1919 |
7.38% 486/2016 |
-13.42% 902/2113 |
0.24% 1519/2208 |
| 2021 | -4.12% 941/1822 |
-3.97% 839/1255 |
6.58% 735/1330 |
-8.96% 1163/1466 |
2.88% 503/1822 |
| 2020 | 42.13% 276/1250 |
-8.98% 645/1028 |
14.21% 565/1067 |
17.00% 122/1164 |
16.86% 147/1184 |
| 2019 | 40.69% 248/1092 |
26.74% 382/739 |
1.67% 113/788 |
3.21% 264/850 |
5.79% 674/918 |
| 2018 | -20.64% 195/834 |
- - |
-7.57% 172/631 |
1.47% 136/660 |
-12.20% 423/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 融通巨潮100指数C VS. 长安沪深300非周期A(740101) |